Gilde Healthcare Partners

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company based in Denmark, specializing in the discovery and development of RNA-targeted therapies. Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, the company focuses on delivering potent single-stranded LNA-based drug candidates for various disease states. Santaris Pharma's research and development efforts primarily target infectious diseases and cardiometabolic disorders, while also engaging in partnerships with major pharmaceutical companies to address a broader range of therapeutic areas, including cancer, cardiovascular disease, and rare genetic disorders. Founded in 2003, the company holds exclusive worldwide rights for the manufacture and sale of products containing LNA as an active ingredient, supporting its goal of obtaining marketing approval for its innovative therapies.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company based in Denmark, specializing in the discovery and development of RNA-targeted therapies. Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, the company focuses on delivering potent single-stranded LNA-based drug candidates for various disease states. Santaris Pharma's research and development efforts primarily target infectious diseases and cardiometabolic disorders, while also engaging in partnerships with major pharmaceutical companies to address a broader range of therapeutic areas, including cancer, cardiovascular disease, and rare genetic disorders. Founded in 2003, the company holds exclusive worldwide rights for the manufacture and sale of products containing LNA as an active ingredient, supporting its goal of obtaining marketing approval for its innovative therapies.

Ascendis Pharma is a biopharmaceutical company that uses its TransCon prodrug technology platform to create long-acting therapies across endocrinology and oncology. The company's TransCon growth hormone targets growth hormone deficiency in children and has completed Phase III development; TransCon PTH is in Phase II for hypoparathyroidism, and TransCon CNP is in Phase II for achondroplasia; it is pursuing preclinical oncology programs and evaluating systemic and localized delivery; the platform enables control of exposure via TransCon carrier and linker to determine dosing frequency, with prodrugs releasing the active drug in its native form. Ascendis collaborates with Sanofi to co-develop TransCon technologies for diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.